Abstracts tagged "Epidemiology"

Abstract Number: 0815 • ACR Convergence 2020
Initial Pharmaceutical Management in a National Cohort of Elderly-Onset Rheumatoid Arthritis Patients
Deepan Dalal¹, Tingting Zhang², Hiren Varma² and Theresa Shireman², ¹Brown University, East Providence, RI, ²Brown University, Providence, RI
Background/Purpose: Methotrexate is the preferred initial drug for treatment of rheumatoid arthritis (RA) per American College of Rheumatology guidelines (2015). People with elderly-onset RA, classified as onset…
Abstract Number: 1023 • ACR Convergence 2020
Epidemiology and Sociodemographic Distribution of Upper Gastrointestinal Bleeding Among Medicaid Beneficiaries with Systemic Lupus Erythematosus
Chang Xu¹, Molly Perencevich², Seoyoung Kim², Karen Costenbader³ and Candace Feldman¹, ¹Brigham and Women's Hospital, Boston, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Individuals with systemic lupus erythematosus (SLE) have multiple risk factors for upper gastrointestinal bleeding (UGIB), including heightened susceptibility to infection and glucocorticoid, NSAID and…
Abstract Number: 1140 • ACR Convergence 2020
How Did SARS-CoV2/COVID-19 Pandemic Affected Patients with Rheumatic Diseases in Latin America? A Regional Survey from PANLAR
Daniel Fernández-Ávila¹, Julián Barahona-Correa¹, Diana Romero-Alvernia¹, Sergio Kowalski², Ana María Sapag Durán³, Antonio Cachafeiro Vilar⁴, Belia Lucía Meléndez Muñoz⁵, Carlos Santiago Pastelín⁶, Claudia Ramírez⁷, Daniel Palleiro Rivero⁸, Diego Alejandro Jaimes⁹, Dina María Arrieta¹⁰, Guillermo Pons-Estel¹¹, Jossiell Then Báez¹², Manuel Ugarte-Gil¹³, Mario Cardiel¹⁴, Nelly Colman¹⁵, Nilmo Chávez Pérez¹⁶, Paula Burgos¹⁷, Rubén Montufar¹⁸, Sayonara Sandino¹⁹, Yurilis Fuentes-Silva²⁰ and Enrique Soriano²¹, ¹Pontificia Universidad Javeriana - Hospital Universitario San Ignacio, Bogota, Colombia, ²Unidad de Investigación PANLAR. Universidade Federal do Paraná, Paraná, Brazil, ³Hospital Universitario Japonés, Santa Cruz, Bolivia, ⁴Pacífica Salud - Hospital Punta Pacífica,, Ciudad de Panamá, Panama, ⁵Hospital de la Policía Nacional N1 Quito, Quito, Ecuador, ⁶Instituto Hondureño de la Seguridad Social, Tegucigalpa, Honduras, ⁷Organización Keralty, Bogota, ⁸Instituto Nacional de Reumatología del Uruguay - Universidad de la República, Montevideo, Uruguay, ⁹Clínicos IPS- Universidad de la Sabana, Bogotá D.C., Colombia, ¹⁰Hospital México, San José de Costa Rica, Costa Rica, ¹¹Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ¹²Hospital Metropolitano de Santiago (HOMS), Santiago, Dominican Republic, ¹³Servicio de Reumatología. Hospital Nacional Guillermo Almenara Irigoyen and Universidad Científica del Sur, Lima, Peru, ¹⁴Centro de Investigación Clínica de Morelia, Morelia, Mexico, ¹⁵Hospital de Clínicas - Universidad Nacional de Asunción, Asunción, Paraguay, ¹⁶Instituto Guatemalteco de Seguridad Social, Ciudad de Guatemala, Guatemala, ¹⁷Universidad Católica de Chile, Santiago de Chile, Chile, ¹⁸Consultorio de Especialidades del Instituto Salvadoreño del Seguro Social, San Salvador, El Salvador, ¹⁹Policlínica Nicaragüense, Managua, Nicaragua, ²⁰Centro Clínico Universitario de Oriente - Universidad de Oriente, Ciudad Bolivar, Venezuela, ²¹Department of Public Health, Instituto Universitario, Escuela de Medicina Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; Rheumatology Unit, Internal Medicine Services, Hospital Italiano de Buenos Aires, Capital Federal, Buenos Aires, Argentina
Background/Purpose: Social isolation during SARS-CoV-2/COVID-19 pandemic has undermined follow-up of patients with rheumatic diseases. These patients face a critical dilemma between the risk of exposure…
Abstract Number: 1475 • ACR Convergence 2020
Predictors of Thirty-Day Hospital Readmissions in Systemic Lupus Erythematosus in the US: A Nationwide Study
Rayan Najjar¹, Swetha Ann Alexander², Grant Hughes¹, Jinoos Yazdany³ and Namrata Singh⁴, ¹University of Washington, Seattle, WA, ²University of Connecticut, Hartford, CT, ³UCSF, San Francisco, CA, ⁴University of Washington, Bellevue, WA
Background/Purpose: For individuals with systemic lupus erythematosus (SLE), hospital readmission rate is associated with quality of care and prognosis. Our objective was to evaluate independent…
Abstract Number: 1841 • ACR Convergence 2020
Outcomes After Hydroxychloroquine Reduction or Discontinuation in a Multinational Inception Cohort of Systemic Lupus
Celline Almeida-Brasil¹, John Hanly², Murray Urowitz³, Ann Clarke⁴, Rosalind Ramsey-Goldman⁵, Caroline Gordon⁶, Michelle Petri⁷, Ellen M Ginzler⁸, Daniel J Wallace⁹, Sang-Cheol Bae¹⁰, Juanita Romero-Diaz¹¹, Mary Ann Dooley¹², Christine A. Peschken¹³, David Isenberg¹⁴, Anisur Rahman¹⁴, Susan Manzi¹⁵, Søren Jacobsen¹⁶, S. Sam Lim¹⁷, Ronald Van Vollenhoven¹⁸, Ola Nived¹⁹, Andreas Jönsen¹⁹, Diane Kamen²⁰, Cynthia Aranow²¹, Guillermo Ruiz-Irastorza²², Jorge Sanchez-Guerrero²³, Dafna Gladman²⁴, Paul Fortin²⁵, Graciela Alarcón²⁶, Joan Merrill²⁷, Kenneth Kalunian²⁸, Manuel Ramos-Casals²⁹, Kristjan Steinsson³⁰, Asad Zoma³¹, Anca Askanase³², Munther Khamashta³³, Ian Bruce³⁴, Murat Inanc³⁵ and Sasha Bernatsky³⁶, ¹McGill University, Montreal, Canada, ²QEII Health Sciences Centre, Halifax, Canada, ³University Health Network, University of Toronto, Toronto, ON, Canada, ⁴University of Calgary, Calgary, Canada, ⁵Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁶University of Birmingham, Birmingham, England, United Kingdom, ⁷Johns Hopkins University School of Medicine, Baltimore, ⁸SUNY Downstate Health Sciences University, Brooklyn, ⁹Cedars-Sinai Medical Center, Beverly Hills, CA, ¹⁰Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ¹¹Salvador Zubirán National Institute of Health Sciences and Nutrition, Mexico City, Mexico, ¹²UNC Health, Chapel Hil, ¹³University of Manitoba, Winnipeg, Canada, ¹⁴University College London, London, United Kingdom, ¹⁵Temple University, Philadelphia, ¹⁶University of Copenhagen, Copenhagen, Denmark, ¹⁷Emory University, Atlanta, GA, ¹⁸University of Amsterdam, Amsterdam, Netherlands, ¹⁹Lund University, Lund, Sweden, ²⁰Medical University of South Carolina, Charleston, SC, ²¹Feinstein Institutes for Medical Research, Manhasset, NY, ²²Hospital Universitario Cruces, Bizkaia, Spain, ²³University of Toronto, Toronto, Canada, ²⁴Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ²⁵CHU de Quebec - Universite Laval, Quebec, Canada, ²⁶Division of Clinical Immunology and Rheumatology, Department of Medicine, School of Medicine, The University of Alabama at Birmingham; Department of Medicine, School of Medicine; Universidad Peruana Cayetano, Heredia, Alabama, ²⁷New York University, New York, ²⁸University of California San Diego, La Jolla, CA, ²⁹University of Barcelona, Barcelona, Spain, ³⁰Reykjavik University, Reykjavik, Iceland, ³¹University of Glasgow, Glasgow, United Kingdom, ³²Columbia University College of Physicians & Surgeons, New York, NY, ³³King's College London, London, United Kingdom, ³⁴The University of Manchester, Manchester, United Kingdom, ³⁵Department of Rheumatology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, ³⁶The Research Institute of the McGill University Health Centre, Montreal, ON, Canada
Background/Purpose: Hydroxychloroquine (HCQ) is a cornerstone treatment for several autoimmune diseases including Systemic Lupus Erythematosus (SLE). Recently, concerns arose regarding HCQ shortages for SLE patients,…
Abstract Number: 2349 • 2019 ACR/ARP Annual Meeting
Epidemiology, Risk/Prognostic Factors, and Treatment Landscape in Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Systematic Literature Review
Xue Han¹, Leticia Ferri ¹, Grace Crocket ², Sophie Yoon ³, Tracy Slanger ³ and Mir Sohail Fazeli ³, ¹Bristol-Myers Squibb Company, Princeton, NJ, ²Bristol-Myers Squibb; Rutgers University, New York City, NY, ³Doctor Evidence, Santa Monica, CA
Background/Purpose: Interstitial lung disease (ILD) is the most common lung manifestation of RA and the 2nd leading cause of death in RA patients.1,2 The purpose…
Abstract Number: 1098 • 2019 ACR/ARP Annual Meeting
Epidemiology and Mortality of SLE (Systemic Lupus Erythematosus) in Hungary Based on a Nationwide Retrospective Claims Database Study
Melinda Kedves¹, Fruzsina Kósa ², Péter Takács ², Péter Kunovszki ², Jennifer Lofland ³ and György Nagy ⁴, ¹Hospital of Bács-Kiskun County, Department of Rheumatology, Kecskemét, Bacs-Kiskun, Hungary, ²Janssen, GCSO, Budapest, Budapest, Hungary, ³Janssen Scientific Affairs, LLC, Spring House, PA, ⁴Buda Hospital of the Hospitaller Order of Saint John of God, Department of Rheumatology, Budapest, Budapest, Hungary
Background/Purpose: There is little evidence in Hungary on the real incidence, prevalence and mortality of systemic lupus erythematosus (SLE) that is based on a robust…
Abstract Number: 1301 • 2019 ACR/ARP Annual Meeting
Rates of Incident Radiographic Knee Osteoarthritis and Knee Replacement by Sex and Race, Across Three Large, Diverse Cohorts
C. Kent Kwoh¹, Amanda Nelson ², Yvonne Golightly ³, Erin Ashbeck ⁴, Liubov Arbeeva ⁵, Na Wang ⁶, Jeffrey Duryea ⁷ and Tuhina Neogi ⁶, ¹University of Arizona, Tucson, AZ, ²University of North Carolina at Chapel Hill, Chapel Hill, NC, ³University of North Carolina at Chapel Hill Department of Epidemiology and Thurston Arthritis Research Center, Chapel Hill, NC, ⁴The University of Arizona Arthritis Center, University of Arizona, Tuccson, AZ, Tucson, AL, ⁵University of North Carolina at Chapel Hill Thurston Arthritis Research Center, Chapel Hill, NC, ⁶Boston University School of Medicine, Boston, MA, ⁷Harvard Medical School Department of Radiology Brigham and Women's Hospital, Boston, MA
Background/Purpose: Previous studies have suggested differences in the development of incident radiographic knee osteoarthritis (RKOA) and the receipt of knee replacement (KR) by sex and…
Abstract Number: 2051 • 2019 ACR/ARP Annual Meeting
Factors in Achieving Serum Uric Acid Target and the Occurrence of Gouty Arthritis: A Cross-sectional Study Based on Japanese Health Insurance Claim Data
Ruriko Koto¹, Akihiro Nakajima ¹, Hideki Horiuchi ¹ and Hisashi Yamanaka ², ¹Teijin Pharma Limited, Chiyoda-ku, Tokyo, Japan, ²Sanno Medical Center, Minato-ku, Tokyo, Japan
Background/Purpose: The number of gout attacks can be reduced by achieving and maintaining serum uric acid (sUA) at or below 6.0 mg/dL, a level uniformly…
Abstract Number: 654 • 2012 ACR/ARHP Annual Meeting
Incidence Studies of Systemic Lupus Erythematosus in Southern Sweden. Have the Tides Turned
Ragnar Ingvarsson¹, Andreas Jönsen², Ola Nived³, Gunnar Sturfelt⁴ and Anders Bengtsson⁵, ¹Department of Clinical Sciences Lund, Section of Rheumatology, Lund, Sweden, ²Department of Clinical Sciences, Section of Rheumatology, Lund University, Lund, Sweden, ³Department of Clinical Science, Lund University, Rheumatology, Lund, Sweden, ⁴Department of Clinical Sciences Lund, Section of Rheumatology, Lund University, Lund, Sweden, ⁵Department of Rheumatology, University Hospital Lund, Lund, Sweden
Background/Purpose: The main objective was to study the incidence of Systemic Lupus Erythematosus (SLE) within a defined area in Southern Sweden over a period of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].